The recently completed European trial of interferon betahad a greater reduction of cerebral volume in the placebo group (mean reduction at month 36: placebo 5.1%, IFNβ-1b (IFNβ-1b) in patients with secondary progressive 1b 1.8%, P < 0.05) whereas those with Gd-enhancing multiple sclerosis (SP multiple sclerosis) has given an lesions showed a trend to greater reduction of cerebral opportunity to assess the impact of treatment on cerebral volume if the patient was on IFNβ-1b (placebo 2.6%, atrophy using serial MRI. Unenhanced T 1 -weighted brain IFNβ-1b 3.7%; P > 0.05). These results are consistent imaging was acquired in a subgroup of 95 patients from with ongoing tissue loss in both arms of this study of five of the European centres; imaging was performed at secondary progressive multiple sclerosis. This finding 6-month intervals from month 0 to month 36. A blinded is concordant with previous observations that disease observer measured cerebral volume on four contiguous progression, although delayed, is not halted by IFNβ. The 5 mm cerebral hemisphere slices at each time point, using different pattern seen in patients with and without baseline an algorithm with a high level of reproducibility and gadolinium enhancement suggests that part of the cerebral automation. There was a significant and progressive volume reduction observed in IFNβ-treated patients may reduction in cerebral volume in both placebo and treated be due to the anti-inflammatory/antioedematous effect of groups, with a mean reduction of 3.9 and 2.9%, the drug. Longer periods of observation and larger groups respectively, by month 36 (P ⍧ 0.34 between groups). of patients may be needed to detect the effects of treatment Exploratory subgroup analyses indicated that patients on cerebral atrophy in this population of patients with advanced disease without gadolinium (Gd) enhancement at the baseline Keywords: cerebral atrophy; interferon beta-1b; secondary progressive multiple sclerosis; multiple sclerosis; MRI Abbreviations: EDSS ϭ expanded disability status scale; IFNβ-1b ϭ interferon beta-1b; RR ϭ relapsing-remitting; SP ϭ secondary progressive
Summary
The recently completed European trial of interferon betahad a greater reduction of cerebral volume in the placebo group (mean reduction at month 36: placebo 5.1%, IFNβ-1b (IFNβ-1b) in patients with secondary progressive 1b 1.8%, P < 0.05) whereas those with Gd-enhancing multiple sclerosis (SP multiple sclerosis) has given an lesions showed a trend to greater reduction of cerebral opportunity to assess the impact of treatment on cerebral volume if the patient was on IFNβ-1b (placebo 2.6%, atrophy using serial MRI. Unenhanced T 1 -weighted brain IFNβ-1b 3.7%; P > 0.05). These results are consistent imaging was acquired in a subgroup of 95 patients from with ongoing tissue loss in both arms of this study of five of the European centres; imaging was performed at secondary progressive multiple sclerosis. This finding 6-month intervals from month 0 to month 36. A blinded is concordant with previous observations that disease observer measured cerebral volume on four contiguous progression, although delayed, is not halted by IFNβ. The 5 mm cerebral hemisphere slices at each time point, using different pattern seen in patients with and without baseline an algorithm with a high level of reproducibility and gadolinium enhancement suggests that part of the cerebral automation. There was a significant and progressive volume reduction observed in IFNβ-treated patients may reduction in cerebral volume in both placebo and treated be due to the anti-inflammatory/antioedematous effect of groups, with a mean reduction of 3.9 and 2.9%, the drug. Longer periods of observation and larger groups respectively, by month 36 (P ⍧ 0.34 between groups). of patients may be needed to detect the effects of treatment Exploratory subgroup analyses indicated that patients on cerebral atrophy in this population of patients with advanced disease
Introduction
The recently published trial of interferon beta-1b (IFNβ-1b) T 2 lesion volume in the treated group after 3 years (Miller et al., 1999) . This disparity between the magnitude of the in secondary progressive (SP) multiple sclerosis demonstrated a highly significant effect of treatment on the primary clinical treatment effect on MRI and clinical indices has also been noted in a number of other recent phase III studies in earlier outcome-delay of confirmed disability progression-as well as on relapse-related parameters (European Study Group, relapsing-remitting (RR) multiple sclerosis (IFNβ Study Group, 1995 , PRISMS Study Group, 1998 . Consequently, 1998). However, the treatment effect on the primary MRI outcomes was considerably greater: a reduction in monthly appropriate concerns have been raised about the utility of such MRI indices as outcome measures in multiple sclerosis gadolinium-enhancing lesion activity of up to 80% was found on treatment, in association with complete stabilization of treatment trials (Miller et al., 1998) .
The limited nature of the correlation between clinical the most caudal at the level of the velum interpositum cerebri, as this was found to be the most reproducible method progression, assessed with the Expanded Disability Status Scale (EDSS) and the change in T 2 lesion volume, has also covering the region of interest. Next, the algorithm was applied slice by slice, with subsequent review of the been reported in a number of recent studies (Paty et al., 1993; Molyneux et al., 1998) . This is likely to reflect the effectiveness of the extraction process. In a small percentage of slices, the extraction was incomplete, resulting in residual low pathological specificity of standard T 2 -weighted imaging for the more destructive pathological elements of small islands of skull, and these non-brain regions were manually deleted where necessary. demyelination and axonal loss, and makes caution advisable in the interpretation of T 2 lesion volume findings in isolation.
Following extraction and editing, the volume of the extracted brain in the four slices was calculated with inSeveral novel MRI techniques have been developed recently that offer the prospect of selectively monitoring house software (Calc-Vol; L. Wang, Institute of Neurology, University College London, London, UK). Progressive different aspects of the disease process. The European IFNβ-1b trial in SP multiple sclerosis has provided the opportunity atrophy was expressed as change in millilitres per year. For the serial MRI studies of each patient, each study to apply a number of these MRI tools in a large phase III study. In particular, serial measurements of cerebral volume was compared against the baseline image to ensure that repositioning was adequate. When this was not the case, that have been performed in a subgroup of patients in this study, giving an opportunity to study the effect of IFNβ-1b treatment image was excluded from the analysis. on tissue loss in patients with SP multiple sclerosis. The present paper reports the results of this analysis.
Statistical analysis
Comparison between baseline cerebral volumes as defined (i.e. the four contiguous slices rostral to the velum
Methods
Seven hundred and eighteen patients with SP multiple interpositum) in the placebo and treated groups was performed using the Wilcoxon rank sum test. The significance of any sclerosis were recruited from 32 European centres into a randomized, double-blind, placebo-controlled trial of IFNβ-within-group change in cerebral volume from baseline was assessed using a paired t-test for both the placebo and the 1b planned to occupy 3 years. The trial design, the major clinical endpoints and the core MRI protocol have been treated patients. This analysis was performed for both absolute and percentage change in the MRI variables. Statistical described elsewhere (Polman et al., 1995; European Study Group 1998) . In addition to the annual imaging, a subgroup analyses included all data available at a given time, with missing data maintained as missing. In addition, cerebral of 95 patients from five of the 32 European centres underwent T 1 -weighted brain imaging at intervals of 6 months; from volumes at individual last visits (last scan available) were evaluated for all patients who had data available at least once these images an assessment of tissue loss was performed using methods described below. during treatment. Non-parametric analysis of covariance with stratification adjustment for centre and covariance adjustment for baseline cerebral volume was used to assess the significance of any
MRI acquisition
The brain MRI protocol comprised an unenhanced treatment effect on cerebral volume at each time point. Post hoc analysis was performed by stratifying patients into those T 1 -weighted spin-echo (SE) sequence with the following parameters: TR (repetition time) ϭ 500-700 ms; TE (echo with and those without gadolinium enhancement at the baseline and subsequently repeating the analysis. However, time) 5-25 ms; field of view 25 cm; 28 axial oblique, contiguous, interleaved 5 mm slices; matrix 256 ϫ 256; 1 since sample sizes are small in the subgroups of patients with and without gadolinium enhancement at the baseline, or 2 excitations. This protocol was performed at baseline and then at intervals of 6 months until month 36; repositioning was consideration of centres might not be appropriate. Thus, non-parametric analyses of covariance with adjustment for performed with a protocol based on standardized anatomical landmarks (Gallagher et al., 1997) .
baseline cerebral volume alone were used to explore associations between treatment and percentage change from baseline in cerebral volume. In addition, a repeated measures analysis of variance was performed to further investigate
MRI analysis
Measurement of cerebral volume was performed by a single the significance of any treatment effect over the whole study duration. blinded observer using an automated algorithm that first extracted the brain from the skull and CSF spaces, and then
The strength of the relationship between the MRI data and two clinical variables-(i) EDSS and (ii) a composite quantified the volume of the extracted image. Details of the algorithm have been described fully (Losseff et al., 1996) . neuropsychological change score (Rao et al., 1991) -was assessed with Goodman-Kruskal correlation coefficients. This approach was highly reproducible, with a mean scanrescan coefficient of variation of Ͻ1%. The analysis process
The composite neuropsychological change score measured sustained attention and concentration, verbal learning and required an observer to select four contiguous slices, with delayed recall, visuospatial learning and delayed recall, and semantic retrieval (Rao et al., 1991) . The relationship between cerebral volume and the primary MRI variables from the study (T 2 lesion volume and new lesion activity) was also assessed with Goodman-Kruskal correlation coefficients.
Results

Patients (Table 1)
The placebo and treated groups were well matched for baseline cerebral volume as defined (307 and 308 cm 3 in age, duration of multiple sclerosis, number of enhancing lesions, T 2 lesion volume, and EDSS change and number of relapses in the 2 years before the study. The time since Of the 95 patients recruited into the cerebral atrophy protocol, 65 had cerebral volume measured at month 36. The evidence of progressive deterioration and diagnosis of SP multiple sclerosis was longer and EDSS scores were higher dropouts reflect a combination of (i) patients who dropped out of the entire study, or just the imaging protocol (n ϭ20), in the placebo group (P Ͻ 0.01), and the proportion of patients with higher EDSS scores was significantly greater and (ii) MRI studies that were rejected due to inadequate repositioning (n ϭ 10). in the placebo than the IFNβ-1b group (P Ͻ 0.05); none of these group differences was seen in the study cohort as a whole (European Study Group, 1998) . In the present subgroup, 43.5% of the patients on placebo were female
Cerebral volume
The changes in cerebral volume over the study duration compared with 53.1% of the patients on IFNβ-1b; this is in contrast to the study cohort as a whole, in which according to treatment effect are given in Table 2 and Fig. 1 . In the placebo group, a significant 0.89% mean reduction in approximately 60% of patients in both groups were female. Ͻ0.0001 Ͻ0.0001 0.0449 *Non-parametric analysis of covariance with stratification adjustment for centre and covariance adjustment for baseline *Non-parametric analysis of covariance with covariance cerebral volume (except baseline comparison, for which the adjustment for baseline cerebral volume (except baseline Wilcoxon rank sum test was used). † Includes two patients (one comparison, for which the Wilcoxon rank sum test was used). placebo, one IFNβ-1b) without any post-baseline data. ‡ The t test † The t-test was used to assess the significance of within-group was used for significance of within-group changes from baseline. changes from baseline.
there was a mean reduction in cerebral volume of 2.91% compared with baseline. cerebral volume was apparent at 6 months compared with baseline (P ϭ 0.0005) and further reductions were seen There was no significant effect of treatment on the progression of cerebral volume loss at any of the 6-monthly throughout the study, such that by month 36 there was a mean reduction in cerebral volume of 3.86% compared time points, although there was a trend towards greater reduction in cerebral volume at 6 months in the treated group with baseline.
In the treated group, a significant mean reduction in (P ϭ 0.09). Furthermore, the repeated measures analysis of variance did not show a significant treatment effect on cerebral volume of 1.39% was seen at 6 months compared with baseline (P Ͻ 0.0001), and further reductions were cerebral volume (P ϭ 0.14).
Post hoc analysis was performed by stratifying patients identified at subsequent time points, such that by month 36 and treated groups, respectively. There was a significant but adjustment for baseline cerebral volume (except baseline low correlation at baseline between EDSS and cerebral comparison, for which the Wilcoxon rank sum test was used). † The t-test was used to assess the significance of within-group volume for the group as a whole (r ϭ -0.18, P ϭ 0.018).
changes from baseline.
No longitudinal relationship was identified between the change in EDSS and the change in cerebral volume. However, a significant relationship between cerebral volume and the into those with and those without gadolinium enhancement at baseline and subsequently repeating the analysis (Tables 3 composite neuropsychological score at baseline was identified for the group as a whole (r ϭ 0.25, P ϭ 0.007). This and 4, Figs 2 and 3). In the inactive group (no enhancement at baseline), there was a greater loss of cerebral volume at correlation was significant in the placebo group (r ϭ 0.30, P ϭ 0.005) but not in the treated group (r ϭ 0.15, P ϭ0.18). each time point in the placebo than in the treatment group (Fig. 2) . The mean reductions in cerebral volume in this A significant relationship between percentage change in cerebral volume and the composite neuropsychological group at 36 months were 5.1 and 1.8% for the placebo and treated subgroups, respectively (P ϭ 0.0026); significance change score was also identified for the group as a whole (r ϭ 0.23, P Ͻ 0.005), which was also significant in the was not reached at earlier time points. In the group with one or more enhancing lesions at baseline, there was a greater placebo group (r ϭ 0.32, P ϭ 0.002) but not in the treated group (r ϭ 0.14, P ϭ 0.31). loss of cerebral volume in the treated than in the placebo subgroup at all time points (Fig. 3) ; the mean reductions at There was no difference in the rate of cerebral atrophy between patients who had one or more courses of steroids rate of progressive tissue loss) may have been obscured by the effect of acute inflammatory lesions at baseline. Among the during the study and those who did not (data not shown).
A modest correlation, approaching statistical significance, patients with no enhancing lesions at baseline (in whom relatively few enhancing lesions occurred at follow-up even in was found over the study duration between percentage change in T 2 lesion volume and cerebral volume (r ϭ -0.12, P ϭ the placebo group), there was less cerebral volume reduction in the treated than in the placebo group at each time point, and 0.098) and between enhancing lesion activity (measured for months 1-6 and 19-24) and percentage change in cerebral the overall loss of volume in the treated group was less than half of that seen in the placebo group. In contrast, among the volume (r ϭ -0.15, P ϭ 0.059).
patients with at least one enhancing lesion at baseline there was a trend for the treated group to develop more volume loss than the placebo group. This may well reflect the fact that
Discussion
This study documents a decrease in cerebral volume in both IFNβ-1b treatment is associated with resolution of oedema and inflammation in acute multiple sclerosis lesions (Miller et al., treatment groups over a period of 3 years; in contrast to the effect observed on the clinical parameters, and to a much 1999), resulting in a loss of volume that is not solely due to ongoing tissue loss (i.e. demyelination or axonal loss). The greater extent the effect on the established MRI parameters (European Study Group 1999; Miller et al., 1999) , there profound effect of IFNβ-1b in reducing the duration of gadolinium enhancement has been reported recently (Miller was no statistically significant effect of treatment on the development of atrophy. A number of factors might have et al., 1999) , indicating that IFNβ-1b treatment facilitates a more rapid resolution of blood-brain barrier breakdown and contributed to these results.
First, it might be queried whether unblinding of the MRI inflammation. This resolution of oedema and acute inflammatory infiltrate due to treatment could have resulted in an analyst could have influenced the results. This is most unlikely. The analyst was blinded to the treatment status of apparently greater loss of cerebral volume in the treated than in the untreated group. This may have masked a genuine effect the patients and did not have access to their other imaging data, such as T 2 -weighted and gadolinium-enhanced images, of treatment in slowing the rate of ongoing tissue loss in the cohort as a whole. Such an effect may also have contributed to from which the observation of an apparent treatment effect might have led to unblinding. The analyst was unblinded to the apparent uncoupling of the relationship between the change in cerebral volume and the neuropsychological change score the date of the MRI studies; in fact, this was necessary in order to check for repositioning against the baseline study.
in the treated cohort. Furthermore, ongoing enhancing activity in the placebo group, which was considerable in those who had However, knowledge of the scan date should not have affected the results since the technique is almost fully automated enhancing lesions at baseline, may well have masked the true extent of atrophy due to progressive tissue loss in this cohort. and is thus not potentially subject to operator-dependent measurement bias. The average rate of~1% loss of cerebral Notwithstanding the above caveats, it is likely that most of the anti-oedema effect of treatment would occur within tissue per year also accords well with that reported in other studies (Losseff et al., 1996; Fox et al., 2000) . the first few weeks and months, and it is clear that cerebral atrophy continued to accrue in both treatment arms throughout Secondly, it is possible that methodological limitations may have prevented the identification of a genuine treatment the whole study period. This is in contrast to the dramatic and sustained effect of treatment on the well-established effect. This seems unlikely since the technique adopted to measure cerebral volume has an extremely high level of conventional MRI indices of disease activity (gadolinium enhancement) and progression (T 2 lesion volume). It is, reproducibility, with a scan-rescan variability of Ͻ1% (Losseff et al., 1996) . Furthermore, the high level of however, noteworthy that, in terms of magnitude, the results of treatment on cerebral tissue loss more closely matched automation reduced the risk of operator-dependent measurement error and measurement drift over time. The the major clinical outcome measure of disability progression. Thus, disability continued to accrue in the treated group, almost linear reduction in cerebral volume in the placebo group also suggests that it was detecting genuine change albeit to a significantly lesser extent than in the placebo group, and the results of the current study suggest a trend over time. This supports an earlier study in which significant change in cerebral volume was also demonstrated over towards a modest treatment effect on cerebral atrophy, although the lower sample size in this analysis might explain 18 months in a smaller cohort of multiple sclerosis patients (Losseff et al., 1996) . why a significant treatment effect was seen only with the clinical endpoints. However, it seems clear that any effect of Thirdly, the study may have been inadequately powered to detect a treatment effect. Specific power calculations were treatment on the rate of cerebral tissue loss in this population of patients would be modest. not performed before the study, as there were insufficient natural history data obtained with these new techniques to What mechanisms might account for such an ongoing loss of cerebral tissue in the treated group despite marked allow the estimation of sample size. Furthermore, whereas 95 patients were recruited into the atrophy protocol, only concurrent reduction in acute inflammatory lesions? One possibility is that diffuse tissue atrophy develops in multiple 65 patients had cerebral their volume measured at month 36.
Fourthly, a genuine treatment effect (i. nonetheless occurs in the brain (Filippi et al., 1999; Stevenson Molyneux PD, Filippi M, Barkhof F, Gasperini C, Yousry TA, et al., 2000; Tortorella et al., 2000) . It is therefore possible only marginally significant and then only in the second year Neurology 1999; 53: 751-7. of treatment (Rudick et al., 1999) . Also, the cohort studied mechanisms by which atrophy develops at different stages disease is indeed different.
